Vitrolife expands its Genomics business to the Asia Pacific region

Vitrolife AB (publ) today announced that it will be expanding its distribution of genomic testing kits to the Asia Pacific region (excluding China) in accordance with the Illumina partnership agreement announced in October 2018. The expansion of the territory follows the commercial launch of EmbryoMap during Q2 of this year and requires a payment of USD 3 million (approximately SEK 27 million) to Illumina for the expanded rights. EmbryoMap has been developed by Vitrolife for use on Illumina sequencing instruments.

Vitrolife expects the acquired business to add more than SEK 50 million of revenue in 2022 and to have a marginal positive impact on earnings per share.

Gothenburg, November 25, 2021
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

The information was submitted for publication, through the agency of the contact person set out above, at 4.30 pm CET on November 25, 2021.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/